{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.01","value":"0.0"},{"groupId":"OG001","spread":"0.02","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"337"},{"groupId":"OG001","value":"151"}],"units":"Participants"}],"title":"Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.01","value":"0.0"},{"groupId":"OG001","spread":"0.02","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"232"},{"groupId":"OG001","value":"54"}],"units":"Participants"}],"title":"Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.02","value":"-0.1"},{"groupId":"OG001","spread":"0.03","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"30"}],"units":"Participants"}],"title":"Cycle 4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"337"},{"groupId":"OG001","value":"151"}],"units":"Participants"}],"description":"EQ-5D-5L consisted of 2 components: health state profile and optional VAS. EQ-5D health state profile had 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension has 5 levels: 1= no problem, 2= slight problem, 3= moderate problem, 4= severe problem, and 5= extreme problem. The response levels collected from the EQ-5D-5L five dimensions as a health profile are converted into an EQ-5D-5L index (utility) scores to represent participants' utility value. The range of health utility index score is from -0.285 to 1, where higher value indicates perfect health and a negative value represents a state worse than dead. Change from baseline in EQ-5D-5L health utility index scores was performed by visit (i.e., cycle), using a REML-based MMRM approach.","dispersionType":"Standard Error","groups":[{"description":"Participants received 5 mg of fruquintinib oral capsule in combination with BSC once daily for 3 weeks of continuous dosing followed by a 1-week break during a treatment cycle (Each cycle length was 28 days).","id":"OG000","title":"Fruquintinib + BSC Group"},{"description":"Participants received placebo matched to fruquintinib oral capsule in combination with BSC once daily for 3 weeks of continuous dosing followed by a 1-week break during a treatment cycle (Each cycle length was 28 days).","id":"OG001","title":"Placebo + BSC Group"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"ITT population included all randomized participants. Here, \"Overall Number of Participants Analyzed\" signifies those participants who were evaluable for this outcome measure and \"Number analyzed\" signifies those participants who were evaluable at the specified categories.","reportingStatus":"POSTED","timeFrame":"Baseline, Cycle 2, 3 and 4 (Each cycle=28 days)","title":"Change From Baseline in EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Health Utility Index Scores","type":"SECONDARY","unitOfMeasure":"score on a scale"}